文献速递肝病

美国脂肪性肝病患者病因特异性死亡率研究

Cause-specific mortality in patients with steatotic liver disease in the United States.
PubMed 文献 · J Hepatol · 2025-05-24

该回顾性队列研究纳入美国退伍军人健康管理局2010至2021年366433例影像确诊肝脂肪变性成人,比较MASLD、MetALD与ALD的病因特异性死亡。无肝硬化者心血管病与肝外癌症死亡为主,肝硬化者肝病与心血管病死亡为主;MetALD和ALD肝病死亡风险较MASLD逐步升高。

要点

  • 无肝硬化各亚型10年心血管病与肝外癌症累积死亡率相近。
  • 肝硬化患者中,ALD肝病死亡10年累积发生率22.1%高于MASLD的9.2%。
  • 肝病死亡风险MetALD为MASLD的3.38倍,ALD为6.99倍。

核心结论

  • 无肝硬化时心血管病和肝外癌症是各SLD亚型主要死因,肝硬化时肝病和心血管病死亡占主导。
  • MetALD和ALD较MASLD与逐步升高的肝病死亡风险相关。

研究设计与样本

  • 回顾性队列研究,纳入美国退伍军人健康管理局2010至2021年门诊就诊的影像确诊肝脂肪变性成人366433例。
  • 平均年龄60.5岁,女性占7.7%,非西班牙裔白人占67.6%;MASLD占77.9%,MetALD占17.5%,ALD占4.6%。
  • 中位随访5.4年,主要暴露为SLD亚型,主要结局为按基线肝硬化分层的病因特异性死亡。

主要发现

  • 无肝硬化者10年心血管病与肝外癌症累积死亡率:MASLD为8.1%和7.5%,MetALD为7.5%和7.4%,ALD为8.1%和7.4%。
  • 肝硬化者10年肝病与心血管病累积死亡率:MASLD为9.2%和17.3%,MetALD为17.7%和13.0%,ALD为22.1%和11.5%。
  • 肝病死亡率:非肝硬化MASLD为0.04/100人年,MetALD为0.19/100人年(HR 3.38,95%CI 3.02-3.78),ALD为0.40/100人年(HR 6.99,95%CI 6.08-8.04)。
  • 肝硬化患者中肝病死亡风险逐步升高趋势持续但幅度较小。

临床怎么用

  • 作者认为研究结果强调需要整合策略以应对酒精使用、心血管风险和癌症筛查,从而减少可预防死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Causes of death across steatotic liver disease (SLD) subtypes remain incompletely characterized in routine clinical practice. We aimed to quantify and compare cause-specific mortality in patients with SLD. METHODS: We conducted a retrospective cohort study of adults with imaging-confirmed hepatic steatosis receiving outpatient care in the national Veterans Health Administration (2010-2021). The primary exposure was SLD subtype, including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and their intersection (MetALD). The primary outcome was cause-specific mortality, stratified by baseline cirrhosis. RESULTS: Among 366,433 adults (mean age, 60.5 years; 7.7% female; 67.6% non-Hispanic White), 77.9% had MASLD, 17.5% had MetALD, and 4.6% had ALD. Over a median follow-up of 5.4 years, the 10-year cumulative incidences of cardiovascular disease (CVD)- and extrahepatic cancer-related deaths among patients without cirrhosis were 8.1% and 7.5% for MASLD, 7.5% and 7.4% for MetALD, and 8.1% and 7.4% for ALD. Among patients with cirrhosis, the 10-year cumulative incidences of liver- and CVD-related deaths were 9.2% and 17.3% for MASLD, 17.7% and 13.0% for MetALD, and 22.1% and 11.5% for ALD. Compared with non-cirrhotic MASLD (0.04 per 100 person-years), liver-related mortality was higher for MetALD (0.19 per 100 person-years; hazard ratio 3.38; 95% CI 3.02-3.78) and highest for ALD (0.40 per 100 person-years; hazard ratio 6.99; 95% CI 6.08-8.04). This progressive increase persisted in cirrhosis but was less pronounced. CONCLUSIONS: CVD and extrahepatic cancer were leading causes of death across SLD subtypes in the absence of cirrhosis, while liver- and CVD-related deaths predominated in patients with cirrhosis. MetALD and ALD were associated with progressively higher risks of liver-related mortality compared with MASLD. These findings underscore the need for integrated strategies addressing alcohol use, cardiovascular risk, and cancer screening to reduce preventable deaths. IMPACT AND IMPLICATIONS: Causes of death across the steatotic liver disease (SLD) spectrum remain incompletely characterized in routine clinical settings. In this large nationwide cohort study, we evaluated cause-specific mortality in patients with MASLD, MetALD, and ALD. We showed that cardiovascular disease and extrahepatic cancer were the primary causes of death in patients without cirrhosis across SLD subtypes, while liver disease and cardiovascular disease were predominant in those with cirrhosis. Importantly, MetALD and ALD were associated with progressively increasing risks of liver-related mortality compared to MASLD. Our findings highlight the need for integrated care models that simultaneously address cardiovascular risk factors, implement strategies to reduce alcohol consumption, and promote cancer screening to mitigate preventable deaths in SLD.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Ochoa-Allemant P, Hubbard RA, Kaplan DE, et al. Cause-specific mortality in patients with steatotic liver disease in the United States. J Hepatol. 2025. PMID: 40419118. doi:10.1016/j.jhep.2025.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。